Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Fochon Biosciences Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action is under the review of 1 distinct examiner, WILLIS, DOUGLAS M. As the busiest examiner, WILLIS, DOUGLAS M is responsible for 1 pending office action. The company's current prosecution is limited to 1 distinct art unit, which reflects a specific focus for the pending matter.
With only 1 pending office action, the company's immediate patent strategy is centralized. Practitioners must focus entirely on the preferences and history of WILLIS, DOUGLAS M within the 1 distinct art unit. The lack of multiple pending actions or examiners suggests a high-focus approach to the current portfolio. The 1 pending office action represents the total current workload, meaning the 1 distinct examiner holds complete authority over the immediate results. This streamlined structure allows for a targeted response to the 1 distinct art unit without the complexity of managing multiple examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18711807 | COMPOUNDS AS BCL-2 INHIBITORS | WILLIS, DOUGLAS M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18711807 | COMPOUNDS AS BCL-2 INHIBITORS | WILLIS, DOUGLAS M | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18711807 | COMPOUNDS AS BCL-2 INHIBITORS | WILLIS, DOUGLAS M | 1624 | §103 | Final Rejection | — | Pending | May 20, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFochon Biosciences Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Douglas M Willis has the most, with 1 of Fochon Biosciences Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
